Davita Inc   (DVA)
Other Ticker:  
    Sector  Healthcare    Industry Healthcare Facilities
   Industry Healthcare Facilities
   Sector  Healthcare
Price: $97.0800 $2.37 2.502%
Day's High: $96.7 Week Perf: 2.97 %
Day's Low: $ 95.59 30 Day Perf: 10.12 %
Volume (M): 30 52 Wk High: $ 103.00
Volume (M$): $ 2,905 52 Wk Avg: $83.68
Open: $93.90 52 Wk Low: $65.28

 Market Capitalization (Millions $) 8,978
 Shares Outstanding (Millions) 92
 Employees 69,000
 Revenues (TTM) (Millions $) 11,665
 Net Income (TTM) (Millions $) 747
 Cash Flow (TTM) (Millions $) -9
 Capital Exp. (TTM) (Millions $) 628

Davita Inc

DaVita is a leading provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease, or ESRD. We also provide acute inpatient dialysis services in approximately 700 hospitals and related laboratory services. Dialysis and dialysis related services account for approximately 97% of total net revenues. All other ancillary services and strategic initiatives, which currently account for approximately 3% of our consolidated revenues, relate primarily to our core business of providing renal care services.

Services we provide

Dialysis Services

Outpatient dialysis services

Throughout our network of outpatient dialysis centers, we also provide training, supplies and on-call support services to our peritoneal dialysis patients. With the introduction of smaller, easier to use and portable technologies, we are also providing certain patients the option of home-based hemodialysis, as described above.

As required by law, we contract with a nephrologist or a group of affiliated nephrologists to provide medical director services at each of our centers. In addition, other nephrologists may apply for practice privileges to treat their patients at our centers. Each center has an administrator, typically a registered nurse, who supervises the day-to-day operations of the center and its staff. The staff of each center typically consists of registered nurses, licensed practical or vocational nurses, patient care technicians, a social worker, a registered dietician, biomedical technician support and other administrative and support personnel.

Many of our outpatient dialysis centers offer services for home dialysis patients, primarily CAPD and CCPD. Home dialysis services consist of providing equipment and supplies, training, patient monitoring and follow-up assistance to patients who prefer and are able to receive peritoneal dialysis or home-based hemodialysis treatments in their homes. Registered nurses train patients and their families or other caregivers to perform either peritoneal dialysis or hemodialysis at home.

Under Medicare regulations, we cannot promote, develop or maintain any kind of contractual relationship with our patients which would directly or indirectly obligate a patient to use or continue to use our services, or which would give us any preferential rights other than those related to collecting payments for our services.

Hospital inpatient dialysis services

We provide hospital inpatient dialysis services, excluding physician services, to patients in approximately 700 hospitals. We render these services for a contracted per-treatment fee that is individually negotiated with each hospital. When a hospital requests our services, we typically administer the dialysis treatment at the patient’s bedside or in a dedicated treatment room in the hospital. Hospital inpatient dialysis services are required for patients with acute kidney failure resulting from trauma, patients in the early stages of ESRD and ESRD patients who require hospitalization for other reasons. In 2007, hospital inpatient dialysis services accounted for approximately 5% of our total dialysis treatments.

ESRD laboratory services

We own two separately incorporated, licensed, clinical laboratories, both located in Florida, specializing in ESRD patient testing. These specialized laboratories provide routine laboratory tests covered by the Medicare composite payment rate for dialysis and other physician-prescribed laboratory tests for ESRD patients. Our laboratories provide these tests predominantly for our own ESRD patients throughout the United States. These tests are performed to monitor a patient’s ESRD condition, including the adequacy of dialysis, as well as other diseases a patient may have. Our laboratories utilize information systems which provide information to our dialysis centers regarding critical outcome indicators.

Ancillary services and strategic initiatives

Ancillary services and strategic initiatives, consist of the following:

• Infusion Therapy Services. HomeChoice Partners provides personalized infusion therapy services to patients in their own homes as a cost-effective alternative to inpatient hospitalization. Intravenous and nutritional support therapies are typically managed by registered and/or board-certified professionals including pharmacist, nurses and dieticians in collaboration with the patient’s physician in support of the patient’s ongoing healthcare needs. Revenues are recognized in the period when infusion therapy services are provided.

• Pharmacy. DaVita Rx is a pharmacy that provides oral medications to DaVita’s patients with chronic kidney disease, or CKD, and patients with ESRD. The main objectives of the pharmacy are to improve clinical outcomes, patient compliance and to provide our patients a convenient way to fill their prescription needs. Revenues are recognized as prescriptions are filled and shipped to patients.

• Vascular access services. RMS Lifeline provides management and administrative services to physician-owned vascular access clinics that provide surgical and interventional radiology services for dialysis patients. Management fees generated from these services are included in management fee income and are recognized as earned typically based on a percentage of revenues or cash collections generated by the clinics.

• Disease management services and Special Needs Plans. Village Health provides advanced care management services to health plans and government agencies for employees/members diagnosed with CKD or ESRD. Through a combination of clinical coordination, medical claims analysis and information technology, we endeavor to assist our customers and patients in obtaining superior renal health care and improved clinical outcomes, as well as helping to reduce overall medical costs. Revenues are typically based upon an established contract fee and are recognized as earned over the contract period and can include additional fees for cost savings recognized by certain customers. Village Health also offers full service health care plans for ESRD and CKD patients. The health care business is part of a Medicare Advantage Special Needs Plan that works with the Centers for Medicare and Medicaid Services, or CMS, to provide ESRD patients full service health care. Revenues are recognized as earned and are based on capitated rates as determined by CMS for each patient enrolled in the plan.

• ESRD clinical research programs. DaVita Clinical Research conducts research trials with dialysis patients and provides administrative support for research conducted by DaVita-affiliated nephrology practices. Revenues are based upon an established fee per study, as determined by contract with drug companies and other sponsors and are recognized as earned according to the contract terms.

• Management fee income. We currently operate or provide management and administrative services to 23 outpatient dialysis centers, in which we either own a noncontrolling interest, or are wholly-owned by third parties, under management services agreements. Management fees are established by contract and are recognized as earned typically based on a percentage of revenues or cash collections generated by the centers.

Medicare revenue

Under the Medicare ESRD program, payment rates for dialysis are established by Congress. The Medicare composite rate set by CMS, pays freestanding dialysis facilities for services provided to Medicare beneficiaries under two methods: (1) the composite payment which includes a base payment, adjusted for case-mix and geography, which has no statutory inflation adjustment mechanism, and a drug add-on payment, which is updated annually to account for changes in drug prices and utilization and (2) separately billable drug reimbursement. Thus, facilities receive a composite payment rate per treatment to cover routine dialysis services, certain pharmaceuticals, routine lab work, and other supplies, as well as a separate payment for pharmaceuticals that are not included in the composite payment rate. The Medicare composite rate is subject to regional differences based upon several factors, including differences in wage levels and is subject to a case mix adjustment methodology designed to link payments more closely with illness severity. We are paid separately for other services and pharmaceuticals, including Epogen®, or EPO, vitamin D analogs and iron supplements. Pharmaceuticals are generally paid at average sale price, or ASP, plus 6% based upon prices set by Medicare. The Medicare payment rates, including separately billable drugs, are not sufficient to cover the average cost of providing a dialysis treatment.

Medicaid revenue

Medicaid programs are state-administered programs partially funded by the federal government. These programs are intended to provide health coverage for patients whose income and assets fall below state-defined levels and who are otherwise uninsured. These programs also serve as supplemental insurance programs for co-insurance payments due from Medicaid-eligible patients with primary coverage under Medicare. Some Medicaid programs also pay for additional services, including some oral medications that are not covered by Medicare. We are an authorized Medicaid provider in the states in which we conduct our business.


The dialysis industry is highly competitive, particularly in terms of acquiring existing dialysis centers. We are facing increased competition in the dialysis industry from large and medium-sized providers which compete directly with us for acquisition targets as well as for individual patients. Acquisitions and patient retention are an important part of our growth strategy and our business could be adversely affected if we are not able to continue to make acquisitions on reasonable terms or if we face significant patient attrition to our competitors. Competition for qualified physicians to act as medical directors and for inpatient dialysis services agreements with hospitals is intense. Occasionally we have also experienced competition from former medical directors or referring physicians who have opened their own dialysis centers. In addition, we experience competitive pressures in connection with negotiating contracts with commercial healthcare payors.

   Company Address: 2000 16th Street Denver, 80202 CO
   Company Phone Number: 631-2100   Stock Exchange / Ticker: NYSE DVA
   DVA is expected to report next financial results on July 31, 2023.

Customers Net Income grew by DVA's Customers Net Profit Margin grew to

11.28 %

5.05 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
THC        7.63% 
HMA        0.19% 
• View Complete Report

Ethema Health Corporation

Revenue were $1.300046 million at the Healthcare Facilities company in the most recent fiscal period

The first quarter of 2023 financial report for Ethema Health Corporation may have reached break-even at $0.00 per share, but the company's surge in revenue is a good sign of things to come. Despite the fact that revenues jumped by an impressive 27.043% to $1.30 million from the same financial reporting period a year before, the net deficit was higher than the previous year at $-0.182 million.
While it is concerning to see an increase in net deficit, it is important to note that operating earnings improved by 0.11% to $0.075026 million. This shows that the company is on the right track and is taking steps towards profitability in the future.

Jrsis Health Care Corp

Jrsis Health Care Corp recognizes $0.00 million charge

Jrsis Health Care Corp, a leading healthcare provider, recently released its financial results for the fiscal first quarter of 2023. The company reported a net deficit of $-0.119 million, a significant drop from the net income of $2.639 million recorded in the same reporting period the year before.
The company's earnings per share also dropped to $0.00, compared to $0.10 a year before and -$0.03 from the preceding reporting period. Meanwhile, the revenue remained unchanged at $0.00 million from $15.62 million in the same reporting period a year before and sequentially from $-15,530.25 million.
The company's net deficit is mainly attributed to its $0.00 million impairment of assets, which significantly impacted its financial standing. Without this impairment of assets, the company would still find it challenging to break even.

Imac Holdings Inc

Breaking down first quarter of 2023 effort, the Healthcare Facilities company's saw that it has confronted impressive obstacles

Imac Holdings Inc Releases Q1 2023 Financial Results: Revenue Tumbled and Net Losses Rose Compared to Last Year
Imac Holdings Inc, a leading provider of healthcare services, recently announced its financial results for the first quarter ended March 31, 2023. Despite some positive developments, the company faced challenges in this reporting season, with a drop in revenue and an increase in net losses. Here are the key details of Imac Holdings' Q1 2023 financial performance:
Revenue: Imac Holdings' revenue for the first quarter of 2023 was $2.09 million, reflecting a decline of 46.255% from the same reporting period a year earlier, when it generated revenue of $3.89 million. Sequentially, the revenue declined by 39.697% compared to the last reporting season, which reported revenue of $3.47 million. The significant drop in revenue can be attributed to various factors, such as the economic slowdown, reduced patient volume, and lower reimbursement rates.
Net Losses: In the first quarter of 2023, Imac Holdings reported a net shortfall of $-3.699 million, which was higher than $-3.162 million a year earlier. This showed that the company's net losses surged compared to last year's reporting season. The increased net losses could be due to higher operating and administrative expenses, lower revenues, and slower reimbursements.

Pacific Health Care Organization Inc

The company announced pressing business environment, during the first quarter of 2023 earnings season

As a journalist and financial analyst, I have been closely following the latest financial results of Pacific Health Care Organization Inc. for the first quarter of 2023. Upon analyzing the company's latest earnings report, there are some notable highlights and areas of concern that need to be discussed.
Firstly, let's take a closer look at Pacific Health Care Organization Inc.'s earnings per share (EPS) for the first quarter of 2023. The good news is that EPS remained unscathed at $0.01 per share, compared to the same period last year. However, it's important to note that EPS was $0.00 in the preceding reporting period. This indicates that there has been some progress but a lot more needs to be done to ensure consistent positive results.

Emmaus Life Sciences Inc

The Healthcare Facilities company has failed to reach profitability despite the epic Surge in revenue at the Emmaus Life Sciences Inc all along the first quarter of 2023

Emmaus Life Sciences Inc. has recently announced excellent financial results with a staggering year-on-year revenue growth of 108.813% amounting to $6.75 million in the first quarter of 2023. However, it is worth noting that Emmaus recorded an increased shortfall per share of $-0.07, a significant jump from $0.00 per share reported in the prior period. Despite this, the company's revenue has surged upwards by 13.879% compared to the previous year's $5.93 million.
The fiscal time-frame ending March 31, 2023, saw Emmaus Life Sciences Inc. record a net shortfall of $-3.527 million, which is considerably higher than the $-1.542 million realized in the previous year.


Davita Inc's Segments
Dialysis & related lab services
 Segment     of total Revenue
Ancillary services & strategic initiatives
 Segment     of total Revenue
 Segment     of total Revenue
• View Complete Report

Davita Inc's Operating Statistics Decrease / Increase
Number of Treatments (thousands)   Number of Treatments (thousands) Decline   
Number of treatment days   Number of treatment days Decline   
Treatments per day (thousands)   Treatments per day (thousands) Decline   
Dialysis revenue per treatment ($)   Dialysis revenue per treatment ($) Decline   


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071